20
Participants
Start Date
June 23, 2022
Primary Completion Date
September 29, 2023
Study Completion Date
September 29, 2023
Upifitimab rilsodotin
Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
Placebo
Placebo controlled arm.
Epworth Richmond, Richmond
Asplundh Cancer Pavilion, Willow Grove
VCU Massey Cancer Center, Richmond
Sarasota Memorial Hospital, Sarasota
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
Kettering Health Cancer Center, Kettering
Karmanos Cancer Institute - Detroit, Detroit
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
University of Wisconsin Clinical Science Center, Madison
Sanford Gynecologic Oncology, Sioux Falls
Avera McKennan d/b/a Avera Research Institute, Sioux Falls
Billings Clinic, Billings
University of Chicago Medical Center, Chicago
Methodist Hospital, Omaha
WK Physicians, Shreveport
Stephenson Cancer Center, Oklahoma City
Texas Oncology - Tyler, Tyler
Texas Oncology - DFWW, Bedford
Texas Oncology P.A. - Austin, Austin
HonorHealth Research Institute - HonorHealth VGPCC Biltmore, Phoenix
The University of Arizona Cancer Center, Tucson
University of New Mexico Cancer Center, Albuquerque
Southwest Women's Oncology, Albuquerque
Women's Cancer Center of Nevada, Las Vegas
Center of Hope, Reno
University of California Los Angeles, Gynecologic Oncology Clinic, Los Angeles
University of California, Irvine Medical Center, Orange
Legacy Good Samaritan Medical Center - Legacy Medical Group - Gynecologic Oncology, Portland
Willamette Valley Cancer Institute and Research Center, Eugene
Sherbrooke University Hospital Centre, Québec
Lead Sponsor
GOG Foundation
NETWORK
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Mersana Therapeutics
INDUSTRY